Posts

Novartis’s Lp(a) drug sharply lowered the biomarker but did not prevent cardiovascular events

on

J&J’s oral Icotyde shows promising PsA results, but higher dose misses statistical mark

on

Zura Bio drops HS program after Phase 2 trial miss

on

CRISPR reports encouraging early zugo-cel responses across autoimmune disease cohorts

on

Vir’s hepatitis D drug combination succeeds in first pivotal study

on

Network Bio and Duke team up to build AI disease models

on

Moderna raises growth outlook as vaccine sales and newer products gain momentum

on

Ziltivekimab lowered inflammation markers, but ZEUS found no cardiovascular-event benefit

on

Moderna’s COVID vaccine sales power a Q3 revenue beat

on

Chai Discovery adds Roche to its AI drug-discovery partnerships

on

FDA expands J&J’s Rybrevant Faspro beyond lung cancer

on

Novartis reports seven newly disclosed tumor cases among Zolgensma patients

on

GeneDx and Mirum launch no-cost genetic testing programs

on